Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31314881 | 1.00 | POLB (0.32) | POLBL3MBTL1 | |
| SCHEMBL1302925 | 0.75 | — | — | |
| SCHEMBL1712699 | 0.75 | — | — | |
| SCHEMBL6205356 | 0.75 | — | — | |
| SCHEMBL12311430 | 0.75 | — | — | |
| SCHEMBL6506120 | 0.75 | — | — | |
| Hydrochloric Acid SCHEMBL28835154 | 0.73 | ALDH1A1 (0.35) | POLBL3MBTL1 | |
| Hydrochloric Acid SCHEMBL28137241 | 0.73 | POLB (0.48) | POLBL3MBTL1 | |
| SCHEMBL6511073 | 0.72 | PSEN1 (0.35) | POLBL3MBTL1 | |
| SCHEMBL5101074 | 0.72 | FFAR1 (0.41) | POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049814-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2025-02-13 | — | — | US | claimed |
| US-12194051-B2 | 5-azaindazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2025-01-14 | — | — | US | claimed |
| US-20250049814-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2025-02-13 | — | — | US | disclosed |
| US-12194051-B2 | 5-azaindazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049814-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA1 | POLB 1218/4885L3MBTL1 4016/4885 |
| US-12194051-B2 | 5-azaindazole derivatives as adenosine receptor antagonists | ADORA2A, ADORA2B, ADORA1 | POLB 1218/4885L3MBTL1 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.